Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Mise à jour : Il y a 4 ans
Référence : NCT01345357

Femme et Homme

Extrait

The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.


Critère d'inclusion

  • Solid Tumors or Mantle Cell Lymphoma

Liens